Prediction of Transporter‐Mediated Drug‐Drug Interactions for Baricitinib-Reference-Cited by-同舟云学术

Prediction of Transporter‐Mediated Drug‐Drug Interactions for Baricitinib

Published:2017-07-27 Issue:6 Volume:10 Page:509-519
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical And Translational Science

Author:

Posada Maria M.¹,Cannady Ellen A.¹,Payne Christopher D.¹,Zhang Xin¹,Bacon James A.¹,Pak Y. Anne¹,Higgins J. William¹²,Shahri Nazila³,Hall Stephen D.¹,Hillgren Kathleen M.¹

Affiliation:

1. Eli Lilly and Company Indianapolis Indiana USA

2. Current address: Organovo Inc. San Diego California USA

3. inVentiv Health Clinical La Jolla California USA

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12486

Reference45 articles.

1. Current concepts in the management of rheumatoid arthritis

2. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers

3. Interactions of Human Organic Anion Transporters with Diuretics

4. Drug transport by Organic Anion Transporters (OATs)

5. 6β-Hydroxycortisol Is an Endogenous Probe for Evaluation of Drug–Drug Interactions Involving a Multispecific Renal Organic Anion Transporter, OAT3/SLC22A8, in Healthy Subjects

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toward an Improved Electrocatalytic Determination of Immunomodulator COVID Medication Baricitinib Using Multiwalled Carbon Nanotube Nickel Hybrid;ACS Applied Bio Materials;2024-05-23

2. Dose Optimization Informed by PBPK Modeling: State‐of‐the Art and Future;Clinical Pharmacology & Therapeutics;2024-04-30

3. Mechanistic Modeling of Empagliflozin: Predicting Pharmacokinetics, Urinary Glucose Excretion, and Investigating Compensatory Role of SGLT1 in Renal Glucose Reabsorption;The Journal of Clinical Pharmacology;2024-02-16

4. Baricitinib and tofacitinib off‐target profile, with a focus on Alzheimer's disease;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2024-01

5. Bewertung von Wechselwirkungen und Dosierungsempfehlungen von synthetischen DMARDs – Evidenz- und konsensbasierte Empfehlungen auf Basis einer systematischen Literatursuche;Zeitschrift für Rheumatologie;2023-10-13